Janus Henderson Investors logo

Janus Henderson Investors

Europe, England, United Kingdom, London

Description

Janus Henderson Investors is an asset manager that helps their clients achieve their financial goals.

Investor Profile

Janus Henderson Investors has made 166 investments, with 24 in the past 12 months and 9% as lead.

Stage Focus

  • Series B (30%)
  • Post Ipo Equity (28%)
  • Series C (17%)
  • Series A (12%)
  • Series D (6%)
  • Series Unknown (2%)
  • Series F (1%)
  • Private Equity (1%)
  • Series E (1%)
  • Convertible Note (1%)

Country Focus

  • United States (88%)
  • Canada (3%)
  • United Kingdom (2%)
  • China (2%)
  • Denmark (1%)
  • The Netherlands (1%)
  • Singapore (1%)
  • Spain (1%)
  • India (1%)
  • Germany (1%)

Industry Focus

  • Biotechnology
  • Health Care
  • Medical
  • Therapeutics
  • Pharmaceutical
  • Life Science
  • Biopharma
  • Oncology
  • Health Diagnostics
  • Genetics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Janus Henderson Investors frequently co-invest with?

OrbiMed
North America, New York, United States, New York
Co-Investments: 28
Wellington Management
North America, Massachusetts, United States, Boston
Co-Investments: 28
Surveyor Capital
North America, Illinois, United States, Chicago
Co-Investments: 37
CA
North America, Massachusetts, United States, Boston
Co-Investments: 43
Adage Capital Management
North America, Massachusetts, United States, Boston
Co-Investments: 24
Biotechnology Value Fund
North America, California, United States, San Francisco
Co-Investments: 25
RA Capital Management
North America, Massachusetts, United States, Boston
Co-Investments: 60
Perceptive Advisors
North America, New York, United States, New York
Co-Investments: 24
Logos Capital
North America, California, United States, San Francisco
Co-Investments: 55
Boxer Capital
North America, Florida, United States, Windermere
Co-Investments: 28

Which angels does Janus Henderson Investors often collaborate with?

PT
North America, California, United States, San Francisco
Shared Deals: 1
SK
North America, California, United States, Los Angeles
Shared Deals: 1
JR
North America, California, United States, San Francisco
Shared Deals: 1
RK
North America, California, United States, Los Angeles
Shared Deals: 1

What are some of recent deals done by Janus Henderson Investors?

LEXEO Therapeutics

New York, New York, United States

LEXEO Therapeutics utilizes gene therapy to treat genetically defined cardiovascular and central nervous system diseases.

BiotechnologyLife ScienceTherapeutics
Post Ipo EquityMay 27, 2025
Amount Raised: $80,000,000
Edgewise Therapeutics

Boulder, Colorado, United States

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.

BiopharmaBiotechnologyHealth Care
Post Ipo EquityApr 2, 2025
Amount Raised: $200,000,000
Heartflow

Mountain View, California, United States

Heartflow is a medical technology company that provides various methods of diagnosis and treatment of cardiovascular disease.

Artificial Intelligence (AI)BiotechnologyHealth CareHealth DiagnosticsMedical
Convertible NoteMar 26, 2025
Amount Raised: $98,000,000
Curevo

Bothell, Washington, United States

Curevo is a clinical-stage biotechnology company developing next-generation, non-mRNA vaccines for infectious diseases.

BiopharmaBiotechnologyHealth CareMedical
Series BMar 17, 2025
Amount Raised: $110,000,000
Bambusa Therapeutics

Boston, Massachusetts, United States

Bambusa Therapeutics operates as biotechnology company.

BiotechnologyHealth CareLife ScienceMedical
Series AFeb 14, 2025
Amount Raised: $90,000,000
Monopar

Wilmette, Illinois, United States

Monopar Therapeutics is an emerging biopharmaceutical company focused on developing orphan oncology compounds.

BiopharmaBiotechnologyDeveloper ToolsHealth CareOncologyTherapeutics
Post Ipo EquityDec 20, 2024
Amount Raised: $40,000,000

Ottimo Pharma develops innovative cancer therapies using PD1-VEGFR2 antibodies.

BiotechnologyHealth CarePharmaceutical
Series ADec 19, 2024
Amount Raised: $140,000,000
Angitia Biopharmaceuticals

Guangzhou, Guangdong, China

Angitia Biopharmaceuticals is a global biotechnology company focusing on the discovery and development of innovative therapeutics.

BiopharmaBiotechnologyHealth CareMedical
Series CDec 11, 2024
Amount Raised: $120,000,000
nChroma Bio

Boston, Massachusetts, United States

nChroma Bio is a cutting-edge biotechnology business that is developing targeted in vivo delivery systems as well as best-in-class cargo.

BiotechnologyMedicalProduct Research
Series UnknownDec 11, 2024
Amount Raised: $75,000,000
Maze Therapeutics

South San Francisco, California, United States

Maze Therapeutics is a biotechnology company that develops precision medicines for renal, cardiovascular, and metabolic diseases.

BiopharmaBiotechnologyGeneticsTherapeutics
Series DDec 3, 2024
Amount Raised: $115,000,000